Company intelligence / Profile preview

CUTISS

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

denovoSkin™ is currently in Phase III clinical trials in Europe. It has shown exceptional safety and efficacy results in Phase 1 trials for burns and reconstructions, and Phase 2 trials for burns and reconstructions. The product has received Orphan Drug Designation from Swissmedic, the European Medicines Agency (EMA), and the US FDA for the treatment of burns. The company has successfully treated its first patient in Boston, a pediatric patient.[2][5]

Therapeutic areas: OtherDermatology
Modalities: Personalized tissue therapyBioengineered skin grafts
Industry: Biotech

Drug pipeline

2 assets

denovoSkin

1 more asset in the full pipeline.

Request access →

Partnerships

Tecan (announced April 14, 2025)

Beyond the preview

Go deeper on CUTISS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUTISS.

Explore the full profile